Reto Brun

Summary

Affiliation: University of Basel
Country: Switzerland

Publications

  1. doi Development of novel drugs for human African trypanosomiasis
    Reto Brun
    Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and, University of Basel, CH 4002 Basel, Switzerland
    Future Microbiol 6:677-91. 2011
  2. doi Abietane diterpenoids from Salvia sahendica--antiprotozoal activity and determination of their absolute configurations
    Samad N Ebrahimi
    Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
    Planta Med 79:150-6. 2013
  3. pmc Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol
    Fabrice E Graf
    Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland
    PLoS Negl Trop Dis 7:e2475. 2013
  4. ncbi Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei
    Stefanie Zimmermann
    Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Bioorg Med Chem 21:7202-9. 2013
  5. pmc Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis
    Tanja Wenzler
    Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Antimicrob Agents Chemother 57:5330-43. 2013
  6. pmc UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells
    Ralf Brunner
    Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, CH 4002 Basel, Switzerland
    J Biol Chem 288:22576-83. 2013
  7. doi Antiparasitic agents: new drugs on the horizon
    Pascal Maser
    Swiss Tropical and Public Health Institute, 4003 Basel, Switzerland
    Curr Opin Pharmacol 12:562-6. 2012
  8. pmc In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
    Sarah Schleiferböck
    Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland
    Drug Des Devel Ther 7:1377-84. 2013
  9. doi Antiprotozoal isoflavan quinones from Abrus precatorius ssp. africanus
    Yoshie Hata
    Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
    Planta Med 79:492-8. 2013
  10. doi Cynaropicrin: the first plant natural product with in vivo activity against Trypanosoma brucei
    Stefanie Zimmermann
    Department of Pharmaceutical Sciences, Division of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, Basel, Switzerland
    Planta Med 78:553-6. 2012

Collaborators

Detail Information

Publications27

  1. doi Development of novel drugs for human African trypanosomiasis
    Reto Brun
    Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and, University of Basel, CH 4002 Basel, Switzerland
    Future Microbiol 6:677-91. 2011
    ..With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill...
  2. doi Abietane diterpenoids from Salvia sahendica--antiprotozoal activity and determination of their absolute configurations
    Samad N Ebrahimi
    Division of Pharmaceutical Biology, University of Basel, Basel, Switzerland
    Planta Med 79:150-6. 2013
    ..falciparum, and from 1.8 µM to over 32.3 µM against T. brucei rhodesiense. The cytotoxic IC50 values ranged from 0.5-15.5 µM. Selectivity indices for P. falciparum were 0.1 to 18.2, and 0.1 to 1.2 for T. brucei rhodesiense...
  3. pmc Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol
    Fabrice E Graf
    Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland
    PLoS Negl Trop Dis 7:e2475. 2013
    ..b. gambiense carrying such mutations correlate with a significantly reduced susceptibility to pentamidine and melarsoprol. ..
  4. ncbi Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei
    Stefanie Zimmermann
    Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Bioorg Med Chem 21:7202-9. 2013
    ..At the same time, the study provides a novel extraction and analysis protocol for components of the trypanosomal thiol metabolism. ..
  5. pmc Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis
    Tanja Wenzler
    Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Antimicrob Agents Chemother 57:5330-43. 2013
    ..In summary, DB829 is a promising preclinical candidate for the treatment of first- and second-stage HAT caused by both Trypanosoma brucei subspecies. ..
  6. pmc UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells
    Ralf Brunner
    Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, CH 4002 Basel, Switzerland
    J Biol Chem 288:22576-83. 2013
    ..We surmise that PfMDR1 may play a role in the antimalarial activity of the piperazine-containing compound ACT-213615. ..
  7. doi Antiparasitic agents: new drugs on the horizon
    Pascal Maser
    Swiss Tropical and Public Health Institute, 4003 Basel, Switzerland
    Curr Opin Pharmacol 12:562-6. 2012
    ..Thus, finally, new therapeutic agents against malaria and sleeping sickness are within reach...
  8. pmc In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
    Sarah Schleiferböck
    Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland
    Drug Des Devel Ther 7:1377-84. 2013
    ..SSJ-183 exhibited a half-life of about 10 hours and no significant differences in absorption or exposure between noninfected and infected mice. SSJ-183 appears to be a promising new lead compound with an attractive antimalarial profile. ..
  9. doi Antiprotozoal isoflavan quinones from Abrus precatorius ssp. africanus
    Yoshie Hata
    Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
    Planta Med 79:492-8. 2013
    ..Compounds 3 and 4 showed strong activity against T. b. rhodesiense (IC50 values of 0.30 and 0.16 µM, respectively) and good selectivity (selectivity indices of 73.7 and 50.5, respectively)...
  10. doi Cynaropicrin: the first plant natural product with in vivo activity against Trypanosoma brucei
    Stefanie Zimmermann
    Department of Pharmaceutical Sciences, Division of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, Basel, Switzerland
    Planta Med 78:553-6. 2012
    ..8, 62, and 9.5 were determined. This is the first report of a plant natural product with potent IN VIVO activity against TRYPANOSOMA BRUCEI...
  11. doi Human African trypanosomiasis
    Reto Brun
    Swiss Tropical Institute, Basel, Switzerland
    Lancet 375:148-59. 2010
    ..WHO has stated that if national control programmes, international organisations, research institutes, and philanthropic partners engage in concerted action, elimination of this disease might even be possible...
  12. pmc Trematocidal activity of praziquantel and artemisinin derivatives: in vitro and in vivo investigations with adult Echinostoma caproni
    Jennifer Keiser
    Swiss Tropical Institute, P O Box, CH 4002 Basel, Switzerland
    Antimicrob Agents Chemother 50:803-5. 2006
    ..In vivo, worm burden reductions of 100% were achieved with single oral doses of praziquantel, artesunate, and artemether at 50, 700, and 1,100 mg/kg of body weight, respectively...
  13. ncbi New developments in human African trypanosomiasis
    Reto Brun
    Swiss Tropical Institute, Parasite Chemotherapy, Basel, Switzerland
    Curr Opin Infect Dis 19:415-20. 2006
    ..To review recent literature on human African trypanosomiasis, focussing on genome sequencing, diagnosis and drug discovery, and typing of trypanosomes...
  14. ncbi Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance
    Sonja C Bernhard
    Swiss Tropical Institute, Socinstr 57, Basel, Switzerland
    Int J Parasitol 37:1443-8. 2007
    ..The melarsoprol-selected population apparently had lost TbAT1, whereas in the pentamidine-selected trypanosome population it was still present...
  15. pmc New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289
    Tanja Wenzler
    Department of Medical Parasitology and Infection Biology, Swiss Tropical Institute, Basel, Switzerland
    Antimicrob Agents Chemother 53:4185-92. 2009
    ..In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug...
  16. ncbi Eflornithine for the treatment of human African trypanosomiasis
    Christian Burri
    Swiss Tropical Institute, Swiss Center for International Health, Socinstrasse 57, P O Box, 4002 Basel, Switzerland
    Parasitol Res 90:S49-52. 2003
    ..Based on its trypanostatic rather than trypanocidal mode of action, it is a rather slow-acting drug...
  17. doi Identification of a new chemical class of antimalarials
    Ralf Brunner
    Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel CH 4002, Switzerland
    J Infect Dis 206:735-43. 2012
    ..falciparum SCID mouse model. ACT-213615 represents a new class of potent antimalarials that merits further investigation for its clinical potential...
  18. pmc Isothermal microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and Plasmodium falciparum
    Tanja Wenzler
    Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
    PLoS Negl Trop Dis 6:e1668. 2012
    ..The method could probably be adapted to other protozoan parasites, especially those growing extracellularly...
  19. pmc Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness
    Marcel Kaiser
    Swiss Tropical and Public Health Institute, Parasite Chemotherapy, Socinstrasse 57, CH 4002 Basel, Switzerland
    Antimicrob Agents Chemother 55:5602-8. 2011
    ..b. gambiense and T. b. rhodesiense forms of human sleeping sickness and both stages of the disease...
  20. doi Human African trypanosomiasis
    Reto Brun
    Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
    Infect Dis Clin North Am 26:261-73. 2012
    ..Elimination of the disease is considered feasible provided better tools for diagnosis and treatment can be made available...
  21. ncbi Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermannii
    Martin Senn
    Department of Chemistry, University of Basel, St Johanns Ring 19, CH 4056 Basel, Switzerland
    J Nat Prod 70:1565-9. 2007
    ....
  22. pmc Bottlenecks and the maintenance of minor genotypes during the life cycle of Trypanosoma brucei
    Michael Oberle
    Swiss Tropical and Public Health Institute, Basel, Switzerland
    PLoS Pathog 6:e1001023. 2010
    ..This is compatible with the epidemic population structure of T. brucei, in which clonal expansion of a few genotypes in a region occurs against a background of frequent recombination between strains...
  23. ncbi Antiplasmodial lanostanes from the Ganoderma lucidum mushroom
    Michael Adams
    Institute of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
    J Nat Prod 73:897-900. 2010
    ..The lanostanes exhibited in vitro antiplasmodial activity with IC(50) values from 6 to greater than 20 microM...
  24. pmc Spiroindolones, a potent compound class for the treatment of malaria
    Matthias Rottmann
    Swiss Tropical and Public Health Institute, Parasite Chemotherapy, CH 4002 Basel, Switzerland
    Science 329:1175-80. 2010
    ..The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model...
  25. pmc A new double-antibody sandwich ELISA targeting Plasmodium falciparum aldolase to evaluate anti-malarial drug sensitivity
    Lucienne Tritten
    Swiss Tropical Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
    Malar J 8:226. 2009
    ..Several other ways to evaluate in vitro anti-malarial activity do exist, all with their own assets and limitations...
  26. doi In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum
    Sandra Hofer
    Swiss Tropical Institute, Socinstrasse 57, CH 4002 Basel, Switzerland
    J Antimicrob Chemother 62:1061-4. 2008
    ....
  27. ncbi A protocol for HPLC-based activity profiling for natural products with activities against tropical parasites
    Michael Adams
    Institute of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, CH 4056 Basel, Switzerland
    Nat Prod Commun 4:1377-81. 2009
    ..The protocol was validated with extracts and positive controls such as Artemisia annua...